Thromboembolic events during continuous vasopressin infusions: A retrospective evaluation

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1383-1389

  Doepker, Bruce A ^a   Lucarelli, Maria R ^a   Lehman, Amy ^b   Shirk, Mary Beth ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Critical care; Hemodynamics; Hypotension; Sepsis; Vasopressin; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 8; CATECHOLAMINE; VASOPRESSIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; HUMAN; HYPOTENSION; INCIDENCE; INTENSIVE CARE; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SHOCK; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CATECHOLAMINES; FEMALE; HEMOSTATICS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK FACTORS; SHOCK; THROMBOEMBOLISM; VASOPRESSINS; VENOUS THROMBOSIS;

EID: 34548179285     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H498     Document Type: Article

References (30)

1. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
2. Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004;24:1050-63.
3. Dunser MW, Fries DR, Schobersberger W, et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg 2004;99:201-6.
4. Grant PJ, Tate GM, Davies JA, Williams NS, Prentice CR. Intra-operative activation of coagulation - a stimulus to thrombosis mediated by vasopressin? Thromb Haemost 1986;55:104-7.
5. Hariman H, Grant PJ, Hughes JR, Booth NA, Davies JA, Prentice CR. Effect of physiological concentrations of vasopressin on components of the fibrinolytic system. Thromb Haemost 1989;61:298-300.
6. Haslam RJ, Rosson GM. Aggregation of human blood platelets by vasopressin. Am J Physiol 1972;223:958-67.
7. Landaburu RH, Castellanos DE, Giavedoni E, Lo Presti CA. Neurohumoral control of blood coagulation. I. Effects of adrenergic drugs or ACTH administration and stress. Acta Physiol Lat Am 1971;21:64-73.
8. Desmopressin and arterial thrombosis. Lancet 1989;938-9.
9. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988;72:1449-55.
10. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994;71:154-5.
11. Stump DL, Hardin TC. The use of vasopressin in the treatment of upper gastrointestinal haemorrhage. Drugs 1990;39:38-53.
12. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27:1416-21.
13. Jolly S, Newton G, Horlick E, et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2005;96:1617-20.
14. Sharma RM, Setlur R. Vasopressin in hemorrhagic shock. Anesth Analg 2005;101:833-4.
15. Tsuneyoshi I, Onomoto M, Yonetani A, Kanmura Y. Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth 2005;19:170-3.
16. Stadlbauer KH, Wenzel V, Krismer AC, Voelckel WG, Lindner KH. Vasopressin during uncontrolled hemorrhagic shock: less bleeding below the diaphragm, more perfusion above. Anesth Analg 2005;101:830-2.
17. Dunser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock: defining the role of arginine vasopressin. Drugs 2003;63:237-56.
18. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8.
19. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
20. Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004;24:1002-12.
21. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):338S-400S.
22. Hosmer D, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley-Interscience Publication, John Wiley & Sons, Inc., 2000.
23. Klinzing S, Simon M, Reinhart K, Bredle D, Meier-Hellman A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646-50.
24. Luckner G, Dunser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005;33:2659-66.
25. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-9.
26. Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394-8.
27. Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994;69:173-80.
28. Obritsch MD, Jung R, Fish DN, MacLaren R. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004;38:1117-22. Epub 3 Jun 2004. DOI 10.1345/aph.1D513
29. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928-48.
30. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005;33:1565-71.